211 related articles for article (PubMed ID: 38137089)
1. The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review.
Longo G; Cicolini A; Orsolini L; Volpe U
Brain Sci; 2023 Nov; 13(12):. PubMed ID: 38137089
[TBL] [Abstract][Full Text] [Related]
2. Illuminating Hope for Mental Health: A Drug Review on Lumateperone.
Tarzian M; Ndrio M; Chique B; Serai J; Thalackal B; Lau J; Fakoya AO
Cureus; 2023 Sep; 15(9):e46143. PubMed ID: 37900490
[TBL] [Abstract][Full Text] [Related]
3. Lumateperone: A Novel Antipsychotic for Schizophrenia.
Greenwood J; Acharya RB; Marcellus V; Rey JA
Ann Pharmacother; 2021 Jan; 55(1):98-104. PubMed ID: 32590907
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D
Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
[TBL] [Abstract][Full Text] [Related]
5. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.
Snyder GL; Vanover KE; Davis RE; Li P; Fienberg A; Mates S
Adv Pharmacol; 2021; 90():253-276. PubMed ID: 33706936
[TBL] [Abstract][Full Text] [Related]
6. Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.
Mazza M; Marano G; Traversi G; Sani G; Janiri L
CNS Neurol Disord Drug Targets; 2020; 19(4):243-247. PubMed ID: 32479249
[TBL] [Abstract][Full Text] [Related]
7. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D
Titulaer J; Radhe O; Danielsson K; Dutheil S; Marcus MM; Jardemark K; Svensson TH; Snyder GL; Ericson M; Davis RE; Konradsson-Geuken Å
Eur Neuropsychopharmacol; 2022 Sep; 62():22-35. PubMed ID: 35878581
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
Correll CU; Vanover KE; Davis RE; Chen R; Satlin A; Mates S
Schizophr Res; 2021 Feb; 228():198-205. PubMed ID: 33453691
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
Suppes T; Durgam S; Kozauer SG; Chen R; Lakkis HD; Davis RE; Satlin A; Vanover KE; Mates S; McIntyre RS; Tohen M
Bipolar Disord; 2023 Sep; 25(6):478-488. PubMed ID: 36779257
[TBL] [Abstract][Full Text] [Related]
10. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review.
Jawad MY; Alnefeesi Y; Ceban F; Lui LMW; Jaberi S; Di Vincenzo JD; Amirbeik L; Chen-Li DCJ; Teopiz K; Phan L; Cao B; Ho R; Rosenblat JD; McIntyre RS
Curr Psychiatry Rep; 2022 Aug; 24(8):359-368. PubMed ID: 35802228
[TBL] [Abstract][Full Text] [Related]
11. Lumateperone: a new treatment approach for neuropsychiatric disorders.
Kumar B; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Dec; 54(12):713-719. PubMed ID: 30596390
[TBL] [Abstract][Full Text] [Related]
12. Lumateperone: First Approval.
Blair HA
Drugs; 2020 Mar; 80(4):417-423. PubMed ID: 32060882
[TBL] [Abstract][Full Text] [Related]
13. Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults.
Abuelazm H; Elsayed OH; El-Mallakh RS
Expert Rev Neurother; 2023; 23(8):751-756. PubMed ID: 37458003
[TBL] [Abstract][Full Text] [Related]
14. Lumateperone for the Treatment of Schizophrenia.
Edinoff A; Wu N; deBoisblanc C; Feltner CO; Norder M; Tzoneva V; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
Psychopharmacol Bull; 2020 Sep; 50(4):32-59. PubMed ID: 33012872
[TBL] [Abstract][Full Text] [Related]
15. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight.
Satodiya RM; Brown VR; Njuguna SW; Bied AM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5):495-499. PubMed ID: 35977031
[TBL] [Abstract][Full Text] [Related]
17. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR; Theodore G
J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
[TBL] [Abstract][Full Text] [Related]
18. The role of lumateperone in the treatment of schizophrenia.
Syed AB; Brašić JR
Ther Adv Psychopharmacol; 2021; 11():20451253211034019. PubMed ID: 34377435
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
Calabrese JR; Durgam S; Satlin A; Vanover KE; Davis RE; Chen R; Kozauer SG; Mates S; Sachs GS
Am J Psychiatry; 2021 Dec; 178(12):1098-1106. PubMed ID: 34551584
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of lumateperone tosylate for the treatment of schizophrenia.
Vyas P; Hwang BJ; Brašić JR
Expert Opin Pharmacother; 2020 Feb; 21(2):139-145. PubMed ID: 31790322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
